Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7917518 | 0.89 | SLC6A1 (0.44) | ERCC5FEN1SLC6A1HPGDGPR52 | |
| SCHEMBL7928727 | 0.89 | SLC6A1 (0.44) | ERCC5FEN1SLC6A1HPGDGPR52 | |
| SCHEMBL7923055 | 0.77 | MTNR1A (0.47) | MAOBKMT2ANPC1RAB9A | |
| SCHEMBL7923057 | 0.77 | MTNR1A (0.47) | MAOBKMT2ANPC1RAB9A | |
| SCHEMBL5724863 | 0.76 | SLC6A1 (0.43) | ERCC5FEN1SLC6A1CHRM3MAOA | |
| SCHEMBL5724891 | 0.76 | SLC6A1 (0.43) | ERCC5FEN1SLC6A1CHRM3MAOA | |
| SCHEMBL8733487 | 0.75 | TSHR (0.45) | ERCC5FEN1CHRM3MAOAMAOB | |
| SCHEMBL1315344 | 0.75 | SLC6A1 (0.36) | ERCC5FEN1SLC6A1CHRM3MAOA | |
| SCHEMBL14415792 | 0.75 | MAOA (0.42) | ERCC5FEN1SLC6A1CHRM3MAOA | |
| SCHEMBL1318497 | 0.72 | SLC6A1 (0.40) | ERCC5FEN1SLC6A1CHRM3GPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6174898-B1 | TREATING FILARIAE IN LYMPHATIC SYSTEM BY ADMINISTERING N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS IN WHICH A SUBSTITUTED ALKYL CHAIN FORMS PART OF N-SUBSTITUENT AND SALTS | NOVO NORDISK A/S (DK) | 2001-01-16 | — | — | US | disclosed |
| EP-0858339-A1 | A METHOD OF TREATING FILARIAE | NOVO NORDISK A/S (DK) | 1998-08-19 | — | — | EP | disclosed |
| EP-0502031-B1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND A PHARMACEUTICAL COMPOSITION | NOVO NORDISK AS (DK) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997017073-A1 | A METHOD OF TREATING FILARIAE | NOVO NORDISK A/S (DK) | 1997-05-15 | — | — | WO | disclosed |
| US-5198451-A | Treatment of epilepsy, inhibitors of gamma-aminobutyric acid uptake from synaptic cleft | NOVO NORDISK A/S (DK) | 1993-03-30 | — | — | US | disclosed |
| EP-0502031-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND A PHARMACEUTICAL COMPOSITION. | NOVO NORDISK AS (DK) | 1992-09-09 | — | — | EP | disclosed |
| WO-1991007389-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND A PHARMACEUTICAL COMPOSITION | NOVO NORDISK A/S (DK) | 1991-05-30 | — | — | WO | disclosed |